NYSE American - Nasdaq Real Time Price USD

OS Therapies Incorporated (OSTX)

1.8700
+0.0500
+(2.75%)
As of 12:06:09 PM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for OSTX

Recent News: OSTX

View More
OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
PR Newswire 6 days ago
OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
Business Wire 10 days ago
OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
Business Wire last month
OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma
Business Wire last month
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040
Business Wire last month
Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies
Business Wire last month
OS Therapies FDA Meeting Request Granted

OS Therapies FDA Meeting Request Granted
Business Wire last month
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
Business Wire 2 months ago
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
Business Wire 2 months ago
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
Business Wire 2 months ago
OS Therapies to Host Analyst Day at NYSE on April 7, 2025

OS Therapies to Host Analyst Day at NYSE on April 7, 2025
Business Wire 2 months ago
View More

Related Tickers

OKUR OnKure Therapeutics, Inc.
2.6350
-0.57%
 
UNCY Unicycive Therapeutics, Inc.
0.7350
+7.87%
 
CLRB Cellectar Biosciences, Inc.
0.3932
-4.84%
 
BRTX BioRestorative Therapies, Inc.
1.6450
-2.08%
 
ADIL Adial Pharmaceuticals, Inc.
0.3467
-0.97%
 
ELAB PMGC Holdings Inc.
2.0400
-1.92%
 
KAPA Kairos Pharma, Ltd.
0.5091
-2.10%
 
PCSA Processa Pharmaceuticals, Inc.
0.2389
-7.58%
 
ELDN Eledon Pharmaceuticals, Inc.
2.8250
-1.57%
 
PLRZ Polyrizon Ltd.
0.8105
-2.93%